IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement.

On April 1, 2017, Imprimis Pharmaceuticals, Inc. (the Company)
entered into a license agreement (the License Agreement) with
Richard L. Lindstrom, M.D. (Dr. Lindstrom).

to the terms of the License Agreement, the Company licensed
certain intellectual property and related rights from Dr.
Lindstrom to develop, formulate, make, sell, and sub-license the
topical ophthalmic solution Klarity^TM used to protect
and rehabilitate the ocular surface (the Product). Under the
terms of the License Agreement, the Company is required to make
royalty payments to Dr. Lindstrom ranging from three percent (3%)
to six percent (6%) of net sales, dependent upon the final
formulation of the Product sold. In addition, the Company is
required to make certain milestone payments to Dr. Lindstrom
including: (i) an initial payment of $50,000 upon execution of
the License Agreement, (ii) a second payment of $50,000 following
the first $50,000 in net sales of the Product; and (iii) a final
payment of $50,000 following the first $100,000 in net sales of
the Product. All of the above referenced milestone payments are
payable at the Companys election in cash or shares of the
Companys restricted common stock.

Dr. Lindstrom is a member of the Companys Board of Directors, and
chairman of its Compensation Committee and a member of its
Nomination and Corporate Governance Committee. Our Board of
Directors has reviewed the license agreement and financials terms
thereof, and does not expect total payments (non-board
compensation) to Dr. Lindstrom will be in excess of $120,000
during the next twelve months. Furthermore, the Board of
Directors has determined that entering into the License Agreement
would not impair Dr. Lindstroms independence nor his ability to
provide independent oversight of the Company. The Board of
Directors will continue to monitor Dr. Lindstroms independence in
light of the License Agreement and will take appropriate action
if and when it determines that Dr. Lindstrom is no longer
independent within the rules of The Nasdaq Stock Market.

The foregoing is only a brief description of the License
Agreement does not purport to be a complete description of the
rights and obligations of the parties thereunder and is qualified
in its entirety by reference to the full text of the document,
which is filed as Exhibit 10.1 to this Current Report on Form 8-K
and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

About IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY)

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Recent Trading Information

IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) closed its last trading session up +0.07 at 3.82 with 123,046 shares trading hands.